Day 1Monday, 4 November 2024

Location: Exhibit Stage

Huonslab Co., Ltd., a subsidiary of Huons Global Co., Ltd., South Korea (KOSDAQ: 084110), was established in 2018 under the leadership of Huons Group Chairman Sung Tae Yoon. Huonslab is dedicated to advancing biologics research and development with a pioneering spirit. Central to its mission is the development of innovative drug delivery technologies such as HYDIFFUZE™ for universal antibody Sub-Q delivery based on recombinant human hyaluronidase PH20. With a robust pipeline that includes HLB3-002 ( currently in pivotal Phase 1, rHuPH20, dispersion agent, BLA aimed in 2026 in Korea) and ongoing non-clinical developments in Alzheimer’s, Obesity, and Diabetes, Huonslab exemplifies a commitment to addressing unmet medical needs of patients. Huons Global Co., Ltd., the parent company, is a publicly traded holding company listed on the KOSDAQ since 2006, encompassing 11 subsidiaries specialized in Bio, Pharmaceuticals, and Healthcare. With over 2,200 employees worldwide, Huons Global has demonstrated consistent corporate profitability, achieving a 19-year Compound Annual Growth Rate (CAGR) of 19%. In 2023, Huons Global reported approximately $583 million in sales revenue, marking a 14% increase from the previous year, and an operating profit of approximately $88 million, a 33% rise year-over-year.

Location: Exhibit Stage

DelSiTech is the leader in using and developing biodegradable, amorphous silica (SiO2) matrix and sol-gel encapsulation technologies in drug delivery. The applicability of Silica Matrix technology is widespread. Silica matrix technology enables parenteral drug delivery routes such as subcutaneous, intramuscular, intraocular, and topical delivery, among many others. In addition, the therapeutic indications that the company is working on include metabolic diseases, musculoskeletal diseases, infectious diseases, oncology, and pain.

Location: Exhibit Stage

AmacaThera is a clinical stage biopharmaceutical company specializing in the development of advanced sustained release hydrogel formulations to solve key delivery challenges with off patent and proprietary therapeutics. AmacaThera is developing a pipeline of of pain management and oncology assets including AMT-143, a slow release non-opioid local anesthetic for pain. AmacaThera is dedicated to transforming therapeutics to make a difference in patient health.

Location: Exhibit Stage

Insilico Medicine is a leading generative AI-driven biotech company. Our mission is to accelerate drug discovery and development by leveraging our robust Pharma.AI platform and robotics across biology, chemistry and clinical development. With 31 programs in pipeline including a Phase 2 asset, 6 Phase I assets and multiple pre- clinical stage assets, our generative AI platform helps us advance the pipeline of novel drug candidates rapidly and effectively in oncology, fibrosis, immunology, anemia, and beyond.

Location: Exhibit Stage

Origenis developed an integrated, largely automated and self-learning technology platform ranging from identification and analysis of innovative targets, design of lead structures/lead structure classes, their pharmacokinetic and metabolic optimization, to patentability searches. A special component of our technology suite and expertise is the ability to specifically design molecules crossing of the blood-brain barrier. After spinning out our LRRK2 inhibitor program in Neuron23, a California-based company, supported by blue chip investors like SoftBank, Westlake, Kleiner Perkins, Perceptive, Cowen Healthcare Investments, Redmile Group, HBM and Surveyor Capital, we focussed on our internal pipeline:

• Our most advanced program – inhibition of CDK9 – is in IND enabling toxicology studies. CDK9 has garnered high interest as one of the central switches in tumor development and progression. Origenis is the only player with a CDK9 program being highly potent, extremely selective and with the ability to efficiently cross the blood-brain barrier, thereby providing inroads also for forms of cancer and viral infections in the brain.

• In our pipeline we are working on selective inhibitors of CDK2, CDK16, CDK3, CDK17 and CDK5. Further CDK´s like CDK13, CDK14, CDK4, CDK6 and CDK8 are under consideration. Furthermore we are progressing a NIK inhibitor program, providing - among other indications - a promising approach to target cholangiocarcinoma and certain inflammatory diseases. We pursue a spin off strategy, where assets are transferred in own legal entities, which get staffed and funded separately.

Location: Exhibit Stage

Pioneering Medicines is Flagship Pioneering’s in house drug discovery and development unit. Pioneering Medicines was formed to accelerate the creation of novel therapeutics and maximize the value creation and patient impact of Flagship’s first-in-category bioplatforms. We’re here to make new medicines for patients, sooner. Our team of drug development experts creates new therapeutics built from Flagship’s innovative bioplatforms and novel modalities. More than 40 companies across the Flagship ecosystem are pioneering innovative platform technologies to address major challenges in human health. Pioneering Medicines explores and identifies new product concepts and then works jointly with Flagship’s companies to form integrated teams that advance medicines through robust discovery and early clinical development. Pioneering Medicines also partners with external collaborators across biopharma throughout our R&D process. We apply our unique approach to the R&D priorities of our partners through highly co-creative relationships that draw on the expertise of our respective teams.

Location: Exhibit Stage

Rejuvenate Biomed is a clinical-stage biotechnology company developing therapeutics that target the root causes of age-related diseases. Utilizing two clinically validated proprietary drug discovery platforms, the AI-enabled in silico CombinAgeTM and in vivo CelegAgeTM, Rejuvenate Biomed has built a pipeline of five unique combination drugs targeting different age-related diseases, including neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative indications. Its lead Phase 2-ready asset, RJx-01, has already demonstrated significant potential in treating sarcopenia. The company’s disease agnostic drug discovery platforms continue to provide insight into future therapeutics, driving pipeline growth and potential partnerships. Based in Belgium, Rejuvenate Biomed is dedicated to promoting healthy aging.

Location: Exhibit Stage

Veritas In Silico is unveiling the mysteries of RNA and harnessing the potential of messenger RNA (mRNA) as a drug target. Powered by our proprietary in silico technology, we have established an entirely new system for drug discovery that focuses on finding drugs against structural motifs on mRNA.
The discovery of drugs that target mRNA is a promising direction for drug development and a new paradigm for the pharmaceutical industry. It has the potential for application to any disease, including those for which conventional protein-targeted discovery has not yielded effective treatments.
Veritas In Silico’s mission is to build a warm society where every patient, especially those with diseases that currently have no satisfactory treatment, can look forward to a brighter future through the realization of mRNA-targeted drugs.

Location: Exhibit Stage

Op2Lysis is a French-Belgian biotech company focused on the development of innovative new treatments for patients with cerebrovascular thrombotic diseases, entering clinical phase early 2025. Looking to raise up to €11M EUR in capital, to complete their €27M EUR Series A round. The proceeds will be used to (i) complete a combined Phase 1/2 clinical study of their lead asset O2L-001 in patients with supra-tentorial hemorrhagic stroke and (ii) develop their pipeline of thrombolytic agents, based on their unique NANOp2Lysis® platform, for indications such as infra-tentorial hemorrhagic stroke and ischemic stroke. • Op2Lysis is offering a breakthrough technology accessible to any hospital in order to reduce patient dependency and associated costs. Development choices are based on an existing documented clinical proof of concept. Op2lysis researches and develops innovative medicines whose purpose is to lyse hematoma and blood clot formed during thrombosis in the brain. • Op2Lysis is led by an experienced team that combines biopharma, technology, cardiovascular/neuroscience, clinical and project management and business expertise, and backed by a robust BoD and renown SAB. • Op2Lysis’ team has demonstrated the capacity to raise equity capital (€2.8M) and to secure non-dilutive funds from European Innovation Council accelerator, bpifrance and Wallonia funds. • De-risked pharmaceutical (industrial manufacturing process scale-up) and clinical developments (pre-IND meeting already held with the FDA, clinical study design successfully applied previously). • Potential for accelerated/conditional approval as soon as 2028, market exclusivity and favorable pricings in a favorable competitive landscape (unmet medical need for a life-threatening condition for which there is no approved treatment yet) - Orphan Drug Designations already granted by the FDA and the EMA • Sales potential (> € 1B peak sales anticipated by 2032)

Location: Exhibit Stage

Azafaros is a clinical-stage company founded in 2018 by scientists with a deep understanding of rare genetic disease mechanisms, using discoveries made by scientists at Leiden University and Amsterdam UMC. Azafaros is led by a team of highly experienced industry experts and aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. The Azafaros team is dedicated to rapidly bring new drugs to the rare disease patients who need them. The company is supported by a syndicate of leading Dutch and Swiss investors including Forbion, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.

Location: Exhibit Stage

PRG S&Tech is a company specializing in the research and development of treatments for rare genetic diseases. Developing non-marketable treatments for such diseases is inherently challenging, especially given the difficult business environment in the pharmaceutical industry. However, we are committed to honoring the dignity and value of every single life. Our mission is to develop the world’s first-in-class new drugs for patients suffering from incurable diseases and to become a company that relentlessly pursues the goal of healthy living. We are dedicated to finding effective ways to combat genetic diseases that currently have no cure, driven by our mission: "No one should be left out when it comes to living a healthy life." To achieve this, PRG S&Tech is focused on investigating the causes of rare genetic diseases and developing medicines that target these underlying causes. Our major pipelines under development include treatments for Hutchinson-Gilford Progeria Syndrome (HGPS) and Werner Syndrome (WS), as well as Amyotrophic Lateral Sclerosis (ALS) and Neurofibromatosis Type 2 (NF2). Furthermore, we aim to discover treatments for neurodegenerative diseases, including those related to aging and dementia, through our research on genetic diseases. As Pioneer of Rare Genopathies via Science and Technology, we strive to lead the way in developing innovative treatments and improving the lives of those affected by these conditions.

Location: Exhibit Stage

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

While cancer knows no bounds, neither does the power of human resilience and scientific innovation.

Oncopeptides’ vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

We are science driven, entrepreneurial, and committed to bringing innovation to patients with diseases where there is a clear unmet need.

Oncopeptides’ first drug Pepaxti has been granted full approval for treatment of adult patients with multiple myeloma in Europe.

Our first innovative drug is based on the Peptide Drug Conjugate (PDC) platform, and offers patients robust efficacy, reduces treatment burden and maintains quality of life.

Our pipeline includes other drug candidates built on the PDC platform as well as the Small Polypeptide based Killer Engagers (SPiKE) platform.

We have a values-driven culture and inclusive organization that welcomes people with diverse backgrounds and perspectives.

We are headquartered in Stockholm, Sweden, have 75 coworkers and a modern pre-clinical drug development facility in Solna, outside of Stockholm.

Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

Location: K18

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. Treatment with Tonmya™ (TNX-102 SL, sublingual cyclobenzaprine HCl) in Phase 3 RESILIENT study significantly reduced daily pain and demonstrated broad fibromyalgia symptom improvement, as demonstrated by significant improvement on the primary pain endpoint and on all six key secondary endpoints. RESILIENT was the second Phase 3 study to reach statistical significance on the primary endpoint. New Drug Application (NDA) submission to the FDA on track for the second half of 2024.

Location: K18

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. Herantis plan to start a Phase 1b clinical trial in 2H 2024. The primary aim of this clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson’s disease. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Location: K18

Lumosa Therapeutics is a biotech company dedicated to creating solutions for diseases with urgent unmet medical needs, like stroke. We seek partners to in licensing early stage opportunities in treating neurological diseases. Through Translational research and clinical development, we out-license to partners with global commercial capabilities. Our current pipeline include: LT1001(Naldebain®) for treating Postoperative pain (Marketed); LT3001: Acute ischemic stroke (Phase 2) and LT6001: CSN/ Exosome (Preclinical). With successful experience to partner and commercialize previous product, we see the potential in LT3001 to fulfill the unmet medical need for treating Acute Ischemic Stroke. In the future, Lumosa aims to expand our pipeline, and become an expert for treating neurological diseases.

Location: K18

Stalicla is a global, clinical-stage biotechnology company focused on advancing precision medicine for brain diseases. Founded in 2017, Stalicla has raised over $75m in private capital and non dilutive funding. Stalicla’s shareholders include Novartis, Pictet, Edmond de Rothschild and SPRIM. Stalicla has developed a unique neuro precision platform, DEPI, with a first application in Autism Spectrum Disorder through the clinical development of 2 precision autism assets: STP1 and STP2. STP1 will be entering Phase 2 this year. Stalicla is also advancing STP7 (mavoglurant) licensed from Novartis, into Phase III clinical trials for substance use disorders in partnership with the National Institute of Health. STP7 offers additional multi-faceted late-stage clinical development opportunities in the wider CNS field . STALICLA is now preparing a 75m-Series C to support STP1 & STP2 phase 2, develop STP7 in additional CNS indications and expend its neuro precision pipeline through the in licensing and development of a new PhII asset for which Stalicla has already secured a $24m financing option.

Location: Room K18

Vesper Bio is a private, VC-backed, clinical stage company with world-leading domain expertise in Vps10p domain receptors, developing a rich pipeline of first-in-class small molecule sortilin modulators for a number of critical unmet medical needs within neurodegeneration.

Location: K18

Neuvivo is a private, late-clinical stage biopharmaceutical company dedicated to creating and delivering advanced treatments for ALS and other neurodegenerative diseases. Neuvivo has developed a proprietary technology platform that includes a patented macrophage-targeting technology, NP001, and its manufacture. NP001 is designed to address the heterogeneity and progression of ALS by reducing chronic inflammation through the regulation of the innate immune system, a key factor in the loss of motor and respiratory function in ALS, and pathology seen in other neurological diseases. To date, the treatment has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are diligently working to move this compound toward regulatory approval, with the goal of delivering an effective new treatment to reduce the suffering caused by ALS as early as late 2025.

Location: Room K18

Filament Health (Filament) and Jaguar Health (Jaguar) joined forces in early 2023 to create Magdalena Biosciences, Inc. in order to leverage their mutual expertise in botanical drug development, plant sourcing and sustainable supply, scientific advisors, neuroscience capabilities, regulatory experience with FDA for botanical drug approval, benefit sharing with indigenous populations, expertise in clinical development, manufacturing, bioassay preparation and performance, and Jaguar’s knowledge-based library of plants and extracts. OneSmallPlanet (OSP), who made the seed investment in Magdalena, invests in programs where there is benefit sharing with indigenous populations, including drug development programs. The focus of Magdalena Biosciences, Inc. (Magdalena) is the development of botanical drugs under FDA Botanical Guidance, targeting the initial indications of schizophrenia, attention deficit hyperactivity disorder (ADHD), social anxiety disorder, and depression. In addition, Magdalena has prepared a dossier of safety information from the human experience for the Company's first IND-enabled botanical drug along with the clinical study protocol and drug master file (DMF) and will do so for additional botanical drugs for ADHD, schizophrenia, depression and anxiety, among other neuropsychiatric indications. With pre-IND discussion with FDA, any further in vitro testing or limited toxicology if needed will be performed and Magdalena will be ready to begin clinical studies with Series A funding. Two more botanical drugs will be IND-enabled in 2025. In some cases, the first clinical study will be a Ph 2 study based on centuries of safe use in humans by traditional healers and, sometimes, decades of non-clinical use as a supplement. This process of reaching a POC clinical study within 18 months of program commencement in contrast to the 6 years or more for small molecule drugs, saves time, risk, and money.

Location: K18

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of cancer and auto-immune diseases patients. Clinical-stage programs: - ATN-022: High-affinity antibody allowing the targeting of Claudin 18.2 ultra-low expressors; in Phase II in AUS and China - ORR 41.7% (including responders with ultra-low CLDN 18.2 expression) - ATN-031: Novel and FIC macrophage activator targeting primarily on solid tumors; in Phase I in the US - ATN-037: Ability in reversing prior anti-PD-1 resistance; consistent efficacy observed in NSCLC and melanoma (ORR 33.3%) pts with acquired resistance from prior anti-PD-1 treatment; to start Phase II in AUS and China - ATN-101: Overcoming liver toxicities of 4-1BB targeting therapies and targeting CPI-relapsed/resistant tumors and "cold" tumors not eligible for CPI-treatment; in Phase I in AUS, US and China Pre-clinical-stage programs: - ATG-042 (MTAPnull-selective PRMT5 Inhibitor): brain-penetrable; in vivo efficacy of ATG-042 is significantly better than that of MRTX171; IND ready by early 2025. - AnTenGager platform (proprietary T-cell engager bispecific platform) + In-house developed proprietary CD3 targeting a unique confirmational epitope of CD3 + “2+1” structure and unique TAA-dependent CD3 binding and activation mitigates risk of cytokine release syndrome and hook effect while enhancing efficacy + Multiple novel bispecific antibodies for oncology indications are under pre-clinical development - ATG-201 (CD19 x CD3 bsAb): targeting for the treatment of autoimmune diseases such as SLE, etc. Preclinical studies demonstrated superior efficacy and reduced risk of cytokine release syndrome compared with BMKs; IND-enabling and CMC work is on-going

Location: Room K18

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialization of novel antibody drug conjugate platform technologies. The company has developed a state-of-the-art linker technology comprising of a novel self-immolative group based on Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) chemistry that works with a wide variety of phenolic and non-phenolic payloads. The OPHAS linker was designed to accommodate a wide variety of functional groups and triggering groups. The OHPAS Linker can be triggered by methods that include enzymes (i.e. lysosomal), light, and pH. The resulting ADCs have been shown to be highly stable and have very fast payload release profiles. IntoCell has devised another ADC platform technology called Payload Modified Technology (PMT) in which temporary Modifying Group (MG) has been incorporated into traditional payloads. PMT has shown to improve therapeutic index of ADCs with significant reduction of normal cell’s uptake, resulting in normal cells being minimally affected. By utilizing PMT and OHPAS linker technology, IntoCell has successfully delivered a preclinical candidate in the B7-H3 ADC program. ITC-6146RO, the lead candidate, shows efficacy in various PDX models and has validated stability in mice, rats and NHPs. The IND Submission is planned for 1Q in 2025. Our have also led to the expansion of the OHPAS linker to Topo 1 inhibitors (Camptothecins), notably Nexatecan. Our Her2 ADC, employing Nexatecan, has demonstrated a broader therapeutic index compared to Enhertu in non-GLP cyno toxicity studies. Nexatecan has consistently outperformed Deruxtecan in vivo, across various comparative studies involving Her2, Trop2, and Her3 targets. We are actively pursuing partners worldwide for the development and commercialization of B7-H3 ADC. Additionally, we welcome opportunities for research and development collaborations with parties keen on exploring our proprietary ADC technologies.

Location: Room K18

Novelty Nobility Inc. is a clinical-stage biotech company with locations in Pangyo, South Korea, and Cambridge, U.S. Modest yet bold, we strive to deeply understand what a good, fit-for-purpose antibody is, how it is made, and how we can use it to improve patients’ lives. From neutralizing unwanted antigens or blocking a signaling pathway to delivering immune cells or chemical agents to a specific location, antibodies function in various ways. Our mission is to maximize the potential of therapeutic antibodies by leveraging the drug development principles we pursue - novel science led by noble management. Our science-driven imagination and deep-rooted hands-on expertise in protein discovery and translational development enable us to bring our mission to reality. The most mature assets in our antibody-based drug portfolio are centered on c-Kit as a therapeutic target for retinal disease and c-Kit expressing cancers. Through this pipeline-in-an-asset approach, three internally discovered and developed iterations of our anti-c-Kit antibody are in clinical development in the U.S. NN3201, an antibody drug conjugate (ADC) utilizing MMAE as its payload, is on track to initiate a first-in-human Phase 1 trial for patients with c-Kit associated cancers such as SCLC and GIST starting Q3 2024. NN2101, an anti-c-Kit monoclonal antibody (mAb) has been cleared for Phase 1 study in DME patients while a Phase 1 study of SLRN-517 (formerly NN2802) in chronic urticaria patients is ongoing through our licensee, Acelyrin. Further, we have several promising next-generation preclinical assets in our pipeline including NN4101, a bispecific antibody (bsAb) targeting c-Kit and VEGF for retinal diseases, and NN3206, an ADC with an undisclosed novel target for the treatment of pan-RAS cancers.

Location: Room K18

Sabiad: Pioneering Bacterial Infection Diagnosis and Treatment Sabiad focuses on diagnosing and treating bacterial infections, especially those from surgical procedures like joint replacements. History: Founded in 2022 as a spin-out from the University Medical Center Groningen, Sabiad aims to revolutionize infection detection and treatment, particularly in post-operative care. Early Development: Sabiad’s founders combined expertise in medical microbiology, orthopedics, business, product development, and regulatory affairs to develop StaphMark, addressing gaps in early infection detection and treatment. Pioneering Research: Sabiad discovered the 1D9 antibody with high specificity for Staphylococcus aureus, integrating tracer technology for precise infection imaging. They also developed antimicrobial photodynamic therapy (aPDT) with 1D9-700DX targeting MRSA effectively. Patents and Recognition: Sabiad secured patents EP3080160, US9,944,694 B2, and PCT/NL2014/050857 in the USA and Europe, validating their technology's potential. Growth and Expansion: With substantial funding from grants and venture capital, Sabiad expanded its research, forming key partnerships for preclinical studies and clinical trials. Looking to the Future: Sabiad is poised to impact patient care and the fight against antibiotic resistance, with a roadmap for introducing StaphMark to the market. Healthcare Challenge: Post-operative infections, particularly from MRSA, are challenging to treat due to biofilm formation on implants, making infections difficult to diagnose and eradicate. Differentiating infection from inflammation is also complex, complicating diagnosis and treatment. Sabiad’s Solution: StaphMark, centered around the 1D9 antibody, represents a paradigm shift in detecting and treating S. aureus infections, improving post-operative care.

Location: Room K18

Biomissile Pharmaceuticals Co., Ltd. is a clinical stage biotech company focusing on developing fully human domain antibody (UDAB) and multi-specific antibody (UDAB-M) to fight a range of diseases with global unmet medical needs. We aim to become a premium innovative biopharmaceutical company based on our unique platform technologies, strong pipeline, and outstanding team. We have established five proprietary platforms for rapid antibody discovery and optimization, including the leading platforms for fully human domain antibody (UDAB) and multi-specific antibody (UDAB-M), as well as the largest libraries of phage, yeast and mammalian cell display platforms. Relying on the strong platform technologies, the company has more than 10 innovative candidates under development in a short period of time, including several First-in-Class domain antibodies (UDAB) and multi-specific UDAB-M molecules to specifically activate immune cells in the tumor microenvironment (TME) to treat solid tumors, including TAA-low and ADC-resistant. Presently, two leading projects are in clinical stages (Phase I & II) and the third one is in IND filing stage.

Location Room K12

Menten AI is developing generative AI to design next-generation cyclic peptide therapeutics for challenging drug targets beyond the reach of small molecules and biologics. Its proprietary platform is capable of designing potent and membrane-permeable macrocycles in a matter of days. The team has shown in vitro and in vivo validation of their platform for complex drug targets including protein-protein interfaces (PPIs) and intracellular targets. The company has partnerships with top-10 pharma to accelerate their preclinical drug discovery efforts. Menten AI is backed by top VCs including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y-Combinator.

Location Room K12

DP Technology, established in 2018, is a global pioneer in the "AI for Science" research paradigm. The company is dedicated to solving critical scientific problems by applying advanced Artificial Intelligence and Molecular Simulation algorithms. Our comprehensive computational platform, RiDYMO®, harnesses a deep understanding of physical principles alongside cutting-edge artificial intelligence, unlocking new prospects for structure and dynamics-based drug discovery. DP focuses on three disease areas: autoimmune, neurology and oncology. Currently, we have multiple pipelines under development.

Location Room K12

Pattern Computer, Inc., a Seattle-area AI & ML company, uses its proprietary Pattern Discovery Engine™ (PDE) to successfully discover, patent and test seven new drug combinations to treat two of the top cancers, which are now ready for human trials. The Company applies the PDE to the challenging fields of drug discovery, multiomics, biomarkers and diagnostics, increasing accuracy, predictability data results, discovering patterns that companies can capitalize on. • Pattern Discovery Engine™- discovers and generates valuable hypotheses and insights into complex data, revealing novel patterns that cannot be discovered using conventional techniques or tools • Life Sciences- diagnostics - identifying signatures in 'omics' and focused on combination and repurposed drugs; diagnostic device that is more accurate, uses no reagents, earlier detection, portable, and providing results in 3 seconds with a small sample of saliva, urine or blood- currently working on COVID and more than eight other diseases with our partners, along with projects focusing on toxicity levels and diseases in saliva with the DoD and two national laboratories. Therapeutics – in oncology, as above. • XAI- analytical tools able to reveal the 'how' and 'why' of a system's predictive success – we challenged ourselves to step up from Generative AI and create our PDE to have the ability to tell you how and why of the results. Called “the most advanced ML company on the planet” by the U.S. Department of Energy. • Commercial engagements- include discovering the critical patterns in breast cancer bioindicators in women's tears, allowing partner to bring this product to market; confirming bioindicators in pancreatic cancer detection; improving global prediction rates for colorectal cancer; improving conjunctivitis diagnostics for surgery requirements.

Location Room K12

Private Biotechnology Company. Limited Liability company under Polish law. Three person management board. Supervisory board comprising investors with governance rights

Location Room K12

Alphyn is developing breakthrough therapies to treat the most challenging, severe, and common skin diseases. Our Zabalafin (AB-101) Drug Platform contains multiple bioactive compounds that power a new class of therapeutics capable of attacking disease in numerous ways. This unique approach enables the development of Multi-Target Therapeutics™ that target multiple diseases, and multiple symptoms and causes of each disease target. Alphyn's lead drug candidate for atopic dermatitis (AD), Zabalafin hydrogel (AB-101a), completed Phase 2a clinical trials demonstrating strong efficacy against itch, and the inflammatory and bacterial components of AD, with a strong safety, side effect and patient tolerability profile to be the first AD drug for worry-free continuous and long-term use. Clinical trial results show superiority to current commercialized therapeutics and clinical-stage pipeline candidates. Alphyn's second therapeutic candidate is for epidermolysis bullosa, a collection of rare and life-threatening skin diseases.

Location Room K12

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.

Location Room K12

Cognano is a venture that aims at computer-aided drug discovery. Utilizing large VHH data obtained from alpacas, we are developing a new drug discovery platform to optimize drug design and development. We are actively seeking development partners for our newly identified cancer-specific antigens and antibody drugs. Our focus areas include:

• Triple-negative breast cancer (TNBC)
• Pancreatic cancer
• Small cell lung carcinoma

Location Room K12

Chugai, a member of Roche group, is a Japanese company focused on creating innovative medicinal products which address unmet medical needs. Our innovative antibody technologies have led to multiple therapeutics helping patients around the world. We are the leaders in oncology therapeutics in Japan and have an overall top-level presence in the Japanese pharmaceutical industry.

Our proprietary products, discovered and developed by Chugai, include the anti-IL-6 monoclonal antibody Actemra®/RoActemra® (tocilizumab), ALK inhibitor Alecensa® (alectinib) and anti-FlXa/FX bispecific antibody Hemlibra® (emicizumab), all of which are approved worldwide and illustrate our robust drug R&D capabilities.

Chugai is keen to collaborate with companies with innovative drug discovery technologies. As well, we seek clinical stage licensing opportunities in the oncology, ophthalmology, neuroscience, and immunology areas.

Location Room K12

Kolon Life Science (listed on KOSDAQ), a subsidiary of Kolon Group, is a South Korean biotech company established in 2000. One of its main business areas includes novel biopharmaceuticals, specializing in cell and gene therapies.

There are three gene therapy drug candidates: TG-C for osteoarthritis(US Ph 3 ongoing), KLS-2031 for neuropathic pain (US Ph 1/2a completed), and KLS-3021 as oncolytic virus.

We are currently seeking partners for business development, collaborative research and co-development of our drug assets.

Location: Room K12

Pick up your lunch and join us for this interactive workshop for delegates familiar with partnering who want to up their game. We will cover best practices for collaborating with colleagues, saving time, increasing response rates and acceptance rates, and partneringONE power features to support optimal partnering etiquette. Come away from the session with a clear understanding of how partneringONE can support your company to maximize ROI from partnering, at this and future events. There will be plenty of opportunities to ask our partneringONE expert any questions you may have. This session is limited to 40 people. Please reserve your seat by adding the session to your personal agenda. If you can’t attend a session, drop by the partnering help desk with any questions.

Location: Exhibit Hall Stage

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

Sustainability Focus Area: Social Responsibility